Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

Jianda Yuan, Jun Zhou, Zhiwan Dong, Sapna Tandon, Deborah Kuk, Katherine S. Panageas, Philip Wong, Xinqi Wu, Jarushka Naidoo, David B. Page, Jedd D. Wolchok, F. Stephen Hodi

Research output: Contribution to journalArticle

Abstract

Ipilimumab, an antibody that blocks CTL antigen 4 (CTLA-4), improves overall survival (OS) for patients with metastatic melanoma. Given its role in angiogenesis and immune evasion, serum VEGF levels were evaluated for association with clinical benefit in ipilimumab-treated patients. Sera were collected from 176 patients treated at 3 (n = 98) or 10 mg/kg (n = 68). The VEGF levels before treatment and at induction completion (week 12) were analyzed using the Meso Scale Discovery kit. The association of the levels of VEGF with clinical responses and OS were assessed using the Fisher exact and Kaplan-Meier log-rank tests. VEGF as a continuous variable was associated with OS (P = 0.002). Using 43 pg/mL as the cutoff pretreatment VEGF value defined by maximally selected log-rank statistics, pretreatment VEGF values correlated with clinical benefit at week 24 (P = 0.019; 159 patients evaluable). Pretreatment VEGF ≥ 43 pg/mL was associated with decreased OS (median OS 6.6 vs. 12.9 months, P = 0.006; 7.4 vs. 14.3 months, P = 0.037 for 3 mg/kg; and 6.2 vs. 10.9 months, P = 0.048 for 10 mg/kg). There was no correlation between VEGF changes and clinical outcome. Serum VEGF may be a predictive biomarker for ipilimumab treatment and is worthy of prospective investigation with various forms of immunologic checkpoint blockade.

Original languageEnglish (US)
Pages (from-to)127-132
Number of pages6
JournalCancer immunology research
Volume2
Issue number2
DOIs
StatePublished - Feb 1 2014
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Yuan, J., Zhou, J., Dong, Z., Tandon, S., Kuk, D., Panageas, K. S., Wong, P., Wu, X., Naidoo, J., Page, D. B., Wolchok, J. D., & Hodi, F. S. (2014). Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer immunology research, 2(2), 127-132. https://doi.org/10.1158/2326-6066.CIR-13-0163